文献速递免疫规划卫生政策与健康促进

信息干预降低HPV疫苗犹豫:中国随机调查实验

Effectiveness of information interventions in reducing HPV vaccine hesitancy: a randomized survey experiment in China.
PubMed 文献 · Vaccine · 2026-01-13

个人获益和集体获益信息显著降低犹豫评分,安全信息无显著效果,干预均未改变支付意愿。

要点

  • 个人获益信息使HPV疫苗犹豫评分降低0.85分(95%CI -1.69至-0.19,校正P=0.045)。
  • 集体获益信息使犹豫评分降低1.08分(95%CI -1.89至-0.27,校正P=0.009)。
  • 高犹豫家长中效果更明显,个人和集体获益信息分别降低2.39分和3.02分。

核心结论

  • 简短的个人获益或集体获益信息可在基础信息之上进一步降低家长HPV疫苗犹豫,尤其对高犹豫家长,但不影响支付意愿。

研究设计与样本

  • 共1062名家长随机分入四组(对照组、安全信息组、个人获益组、集体获益组),1002人完成调查并纳入分析。

主要发现

  • 与对照组相比,个人获益组VHS-HPV评分差异为-0.85(95%CI -1.69至-0.19,校正P=0.045)。
  • 集体获益组VHS-HPV评分差异为-1.08(95%CI -1.89至-0.27,校正P=0.009)。
  • 安全信息组差异为-0.36(95%CI -1.23至0.50,校正P=0.410),无统计学显著差异。
  • 高犹豫家长中,个人获益组差异为-2.39(95%CI -4.36至-0.42,校正P=0.018),集体获益组为-3.02(95%CI -4.96至-1.08,校正P=0.003),安全信息组无显著差异(-1.32,95%CI -3.42至0.78,校正P=0.219)。
  • 所有干预均未显著改变支付意愿。

临床怎么用

  • 在官方数字传播中嵌入简短的个人获益或集体获益信息,可能有助于加速中国新纳入国家免疫规划的HPV疫苗接种覆盖。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In September 2025 China announced the inclusion of HPV vaccination in its national immunization program; parental hesitancy remains the major modifiable barrier to rapid coverage expansion among school-age girls. Our study assessed the effectiveness of safety-focused, personal benefit, and collective benefit information interventions (vs. basic information alone) on parental HPV vaccine hesitancy. METHODS: This double-blind, parallel-group randomized online survey was conducted in mainland China (November-December 2023). Parents of unvaccinated girls aged 9-14 years were recruited by quota sampling. Parents were screened as slight or high hesitancy by a single screening question and randomized to four groups. All received basic vaccine information, with groups additionally received: none (control), safety-focused, personal benefit, or collective benefit information. HPV vaccine hesitancy (VHS-HPV) was the primary outcome, parental willingness to pay (WTP) the secondary. Intervention effects were analyzed using generalized linear models with multiple-comparison-adjusted P values. RESULTS: A total of 1062 parents were randomized into four parallel groups (control, safety-focused, personal benefit, and collective benefit), with 1002 completing the survey and included in the analysis. Compared with the control group, VHS-HPV scores were significantly lower in groups exposed to the personal benefit message (difference, -0.85; 95 % CI, -1.69 to -0.19; adjusted P = 0.045) and the collective benefit message (difference, -1.08; 95 % CI, -1.89 to -0.27; adjusted P = 0.009). In contrast, no statistically significant difference was observed in the safety message group (-0.36; 95 % CI, -1.23 to 0.50; adjusted P = 0.410). The effects were more pronounced among parents with higher hesitancy, with significant differences of -2.39 (95 % CI, -4.36 to -0.42; adjusted P = 0.018) for the personal benefit group and - 3.02 (95 % CI, -4.96 to -1.08; adjusted P = 0.003) for the collective benefit group compared to the control, while no significant difference was observed for the safety message group in this subgroup (-1.32; 95 % CI, -3.42 to 0.78, adjusted P = 0.219). Moreover, no intervention significantly altered WTP. CONCLUSIONS: In this large online experiment, brief personal or collective benefit messages reduced parental HPV vaccine hesitancy beyond basic information alone, particularly among highly hesitant parents, without affecting WTP. Embedding such messaging into official digital communications could accelerate uptake under China's newly launched national program. TRIAL REGISTRATION: Registered with the China Clinical Trial Registry under registration number ChiCTR2300073106 (Registered on July 1, 2023; Last Refreshed on: 2023-12-17. Available from: https://www.chictr.org.cn/showproj.html?proj=198347).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lu Y, Zhao W, Xu S, et al. Effectiveness of information interventions in reducing HPV vaccine hesitancy: a randomized survey experiment in China. Vaccine. 2026. PMID: 41534483. doi:10.1016/j.vaccine.2026.128205

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。